Table 3.

Signs, symptoms, and co-morbidities that are positively associated with the increased risk of oGVHD.

Risk factor	Reference(s)	Risk factor	References(s)
Female-to-male allo-HSCT	11, 52, 54, 61	Chronic or acute myeloid leukemia (compared to aplastic anemia)	72
The female sex of recipients	102	Presence of malignant disease	54
Matched related donors	11	Higher age of recipients	54, 102
Matched unrelated donors	54	Age over 27 years of recipients	72
Diabetes mellitus	85	PBSCT	54, 102
Repeated allo-HSCT	85	PBSCT compared to BMT	72
History of aGVHD	102	PBSCT, compared to both BMT and CBT (only for severe oGVHD)	138
History of acute skin GVHD	52	Schirmer’s test value of <10 mm	72
Number of affected organs by stage I cGVHD	85	Schirmer’s test values of ≤10 mm/5 minute before transplantation	54
Grade III-IV aGVHD	54	Presence of dry mouth	72
Grade II/III overall cGVHD	142	Epstein-Barr virus-positive donor	142
Grade I-III oral and skin cGVHD	142	Conjunctival fibrosis and hyperemia	11
Presence of systemic cGVHD	72

(oGVHD, ocular graft-versus-host disease; allo-HSCT, allogeneic hematopoietic stem cell transplantation; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; PBSCT, peripheral blood stem cell transplantation; BMT, bone marrow stem cell transplantation; CBT, cord blood stem cell transplantation; mm, millimeters)